You are here

Study Evaluating TRU-015 in B-Cell Non-Hodgkin's Lymphoma

Last updated on May 10, 2018

FOR MORE INFORMATION
Study Location
Duarte, California, 91010 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
B-Cell Lymphoma
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subjects with CD20-positive, B cell NHL who, after at least 2 prior therapies of
probable clinical benefit, have relapsed or refractory disease. The following
histologies may be included*: lymphoplasmacytic lymphoma (formerly known as
lymphoplasmacytoid lymphoma), splenic marginal zone B cell lymphoma, extranodal
marginal zone B cell lymphoma of mucosa-associated lymphoid tissue, nodal marginal
zone B cell lymphoma, follicular lymphoma, mantle cell lymphoma, diffuse large-cell B
cell lymphoma, and mediastinal large B cell lymphoma. Small lymphocytic lymphoma will
be included if it is a primary diagnosis and if the lymphoma cells are (5000/mm3) in the peripheral blood. *Subjects enrolled in the preliminary efficacy
cohorts must have relapsed, refractory, or persistent follicular lymphoma (persistent
disease defined as computed tomography (CT) positive for 3 months after last
treatment), and must not have received anti-CD20 targeted therapy within 3 months of
receiving the first dose of test article. Subjects may be considered eligible after a
single therapy of probable clinical benefit, if no further standard effective
treatment is available in the opinion of the investigator. Prior CD20
immunophenotyping of tumors to document B cell NHL is acceptable. If such prior
documentation is not available, then the immunophenotype of the current disease must
be documented by fine-needle aspirate or biopsy, or by circulating CD20-positive NHL
cells from peripheral blood before administration of test article.

- At least 1 measurable lesion that is 1.5 cm in at least 1 dimension by CT or magnetic
resonance imaging (MRI), in an area of no prior radiation therapy, or documented
progression in an area that was previously irradiated.

- Recovery to baseline or grade 1 [according to the National Cancer Institute (NCI)
Common Terminology Criteria for Adverse Events (CTCAE), version 3.0] from all acute
adverse effects of prior therapies (excluding alopecia).

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Candidate for potentially curative therapy that is available to the subject, in the
clinical opinion of the investigator.

- Diagnosis of chronic lymphocytic leukemia, Burkitt's lymphoma, primary effusion
lymphoma, and/or precursor B cell lymphoblastic lymphoma.

- Prior treatments: radioimmunotherapy; allogeneic hematopoietic stem cell transplant
(within 6 months of first dose of study drug); chemotherapy, cancer immunosuppressive
therapy, growth factors (except erythropoietin), or investigational agents (within 4
weeks of first dose of study drug); major surgery not related to debulking surgical
procedures (within 3 weeks of first dose of study drug).

NCT00521638
Pfizer
Terminated
Study Evaluating TRU-015 in B-Cell Non-Hodgkin's Lymphoma

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Study Evaluating TRU-015 in B-Cell Non-Hodgkin's Lymphoma
A Phase 1/2 Dose Escalation Study of TRU-015 in Subjects With Relapsed or Refractory B Cell Non-Hodgkin's Lymphoma

This is a study to evaluate the safety and efficacy of TRU-015 in treatment of B-cell Non-Hodgkin's Lymphoma (NHL).

TRU-015 is also currently being evaluated in multiple clinical studies for the treatment of autoimmune disorders. Over 300 patients have received TRU-015 in these studies, and the data observed to date support its safety in patients with autoimmune disorders.

Safety of an escalating dose of 4 weekly infusions of TRU-015 will be evaluated in subjects with relapsed NHL (see inclusion criteria for subtypes).

Once a maximum tolerated dose (MTD) is confirmed or maximum dose to be studied is determined to be safe and well tolerated, an expanded cohort of subjects with relapsed follicular NHL will be evaluated for efficacy.

Not Provided
Interventional
Phase 1
Phase 2
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Lymphoma, B-Cell
Biological: TRU-015
Intravenous administration; 400 mg, 700 mg, or 1000 mg; 1x/week dosing for 4 weeks
Experimental: 1
Intervention: Biological: TRU-015
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
120
April 2008
April 2008   (Final data collection date for primary outcome measure)

Main Inclusion Criteria:

  • Subjects with CD20-positive, B cell NHL who, after at least 2 prior therapies of probable clinical benefit, have relapsed or refractory disease. The following histologies may be included*: lymphoplasmacytic lymphoma (formerly known as lymphoplasmacytoid lymphoma), splenic marginal zone B cell lymphoma, extranodal marginal zone B cell lymphoma of mucosa-associated lymphoid tissue, nodal marginal zone B cell lymphoma, follicular lymphoma, mantle cell lymphoma, diffuse large-cell B cell lymphoma, and mediastinal large B cell lymphoma. Small lymphocytic lymphoma will be included if it is a primary diagnosis and if the lymphoma cells are < 5.0 x 109/L (5000/mm3) in the peripheral blood. *Subjects enrolled in the preliminary efficacy cohorts must have relapsed, refractory, or persistent follicular lymphoma (persistent disease defined as computed tomography (CT) positive for 3 months after last treatment), and must not have received anti-CD20 targeted therapy within 3 months of receiving the first dose of test article. Subjects may be considered eligible after a single therapy of probable clinical benefit, if no further standard effective treatment is available in the opinion of the investigator. Prior CD20 immunophenotyping of tumors to document B cell NHL is acceptable. If such prior documentation is not available, then the immunophenotype of the current disease must be documented by fine-needle aspirate or biopsy, or by circulating CD20-positive NHL cells from peripheral blood before administration of test article.
  • At least 1 measurable lesion that is 1.5 cm in at least 1 dimension by CT or magnetic resonance imaging (MRI), in an area of no prior radiation therapy, or documented progression in an area that was previously irradiated.
  • Recovery to baseline or grade 1 [according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 3.0] from all acute adverse effects of prior therapies (excluding alopecia).

Main Exclusion Criteria:

  • Candidate for potentially curative therapy that is available to the subject, in the clinical opinion of the investigator.
  • Diagnosis of chronic lymphocytic leukemia, Burkitt's lymphoma, primary effusion lymphoma, and/or precursor B cell lymphoblastic lymphoma.
  • Prior treatments: radioimmunotherapy; allogeneic hematopoietic stem cell transplant (within 6 months of first dose of study drug); chemotherapy, cancer immunosuppressive therapy, growth factors (except erythropoietin), or investigational agents (within 4 weeks of first dose of study drug); major surgery not related to debulking surgical procedures (within 3 weeks of first dose of study drug).
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00521638
3206K2-104
No
Not Provided
Not Provided
Wyeth (Registry Contact: Clinical Trial Registry Specialist), Wyeth
Wyeth is now a wholly owned subsidiary of Pfizer
Emergent Product Development Seattle LLC
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
Wyeth is now a wholly owned subsidiary of Pfizer
January 2013

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now